{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:01:08Z","timestamp":1790190068511,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody\u2013drug conjugates have substantially improved outcomes for patients with HER2-positive (HER2+) metastatic breast cancer. Whether these survival gains have translated equitably across racial and ethnic groups remains unclear despite persistent disparities in breast cancer outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using de-identified electronic health record data from the TriNetX Research Network (2010-2024). Adults with HER2+ metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) were included. Overall survival was estimated using Kaplan\u2013Meier methods and compared across racial and ethnic groups. Multivariable Cox models adjusted for age, body mass index, chronic obstructive pulmonary disease, hypertension, diabetes mellitus, and prior lines of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 7462 patients with HER2+ metastatic breast cancer: 5072 non-Hispanic White (68%), 1193 Black (16%), 746 Hispanic (10%), and 298 Asian (4%). Five-year overall survival was highest among Asian (89.9%) and Hispanic (86.3%) patients, followed by non-Hispanic White (84.0%) and Black patients (80.3%) (P\u2009&amp;lt;\u2009.001). Compared with non-Hispanic White patients, Black patients experienced worse overall survival (adjusted hazard ratio [HR] = 1.22, 95% confidence interval [CI] = 1.03 to 1.45; P\u2009=\u2009.03). Survival differences among Asian and Hispanic patients were not observed after multivariable adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with HER2+ metastatic breast cancer treated with HER2-directed antibody\u2013drug conjugates, Black patients experienced persistently inferior survival despite receipt of effective therapies. These findings highlight ongoing inequities and underscore the need for interventions to ensure equitable translation of therapeutic advances across all populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag223","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:36:03Z","timestamp":1783427763000},"source":"Crossref","is-referenced-by-count":1,"title":["Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1337-7843","authenticated-orcid":false,"given":"Zunairah","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7280-3249","authenticated-orcid":false,"given":"Lan","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Medicine, Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1740-5939","authenticated-orcid":false,"given":"Rahul","family":"Thakur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajinkya","family":"Buradkar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]},{"name":"Department of Medicine, King Abdullah University of Science and Technology , Jeddah,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulham","family":"Ombada","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-1313","authenticated-orcid":false,"given":"Song","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-8139","authenticated-orcid":false,"given":"Alfredo","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Badve","sequence":"additional","affiliation":[{"name":"Department of Medicine, Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8112-6590","authenticated-orcid":false,"given":"Thaer","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-0399","authenticated-orcid":false,"given":"Anant","family":"Madabhushi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5246-2088","authenticated-orcid":false,"given":"Ujjwal","family":"Baid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheheryar","family":"Kabraji","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Winship Cancer Institute of Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2026092314205302900_djag223-B1","doi-asserted-by":"publisher","first-page":"101575","DOI":"10.1016\/j.xcrm.2024.101575","article-title":"Emerging treatments in HER2-positive advanced breast cancer: keep raising the bar","volume":"5","author":"Agostinetto","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026092314205302900_djag223-B2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"2026092314205302900_djag223-B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092314205302900_djag223-B4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"2026092314205302900_djag223-B5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2026092314205302900_djag223-B6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092314205302900_djag223-B7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0140-6736","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"2026092314205302900_djag223-B8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"2026092314205302900_djag223-B9","doi-asserted-by":"publisher","first-page":"LBA1008","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1008","article-title":"Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (PTS) with human epidermal growth factor receptor 2\u2013positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): interim results from DESTINY-Breast09","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092314205302900_djag223-B10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2026092314205302900_djag223-B11","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.Can-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"2026092314205302900_djag223-B12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10549-013-2697-5","article-title":"Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer","volume":"141","author":"Rugo","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2026092314205302900_djag223-B13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"key":"2026092314205302900_djag223-B14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2025","journal-title":"Ann Oncol"},{"key":"2026092314205302900_djag223-B15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/jncimonographs\/lgu016","article-title":"The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians","volume":"2014","author":"Pinheiro","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026092314205302900_djag223-B16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/cncr.28587","article-title":"Immigration factors and prostate cancer survival among Hispanic men in California: does neighborhood matter?","volume":"120","author":"Schupp","year":"2014","journal-title":"Cancer"},{"key":"2026092314205302900_djag223-B17","doi-asserted-by":"publisher","first-page":"e258086","DOI":"10.1001\/jamanetworkopen.2025.8086","article-title":"Racial and ethnic disparities in receipt of ERBB2-targeted therapy for breast cancer, 2010-2020","volume":"8","author":"Krishnamurthy","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026092314205302900_djag223-B18","doi-asserted-by":"publisher","first-page":"e007917","DOI":"10.1161\/CIRCOUTCOMES.121.007917","article-title":"Race, racism, and cardiovascular health: applying a social determinants of health framework to racial\/ethnic disparities in cardiovascular disease","volume":"15","author":"Javed","year":"2022","journal-title":"Cir Cardiovasc Qual Outcomes"},{"key":"2026092314205302900_djag223-B19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11892-022-01454-3","article-title":"Social determinants of health, race, and diabetes population health improvement: black\/African Americans as a population exemplar","volume":"22","author":"Hill-Briggs","year":"2022","journal-title":"Curr Diab Rep"},{"key":"2026092314205302900_djag223-B20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1025481505537","article-title":"Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy","volume":"81","author":"Griggs","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"2026092314205302900_djag223-B21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.soc.2023.05.009","article-title":"Addressing inequalities in breast cancer care delivery","volume":"32","author":"Elmore","year":"2023","journal-title":"Surg Oncol Clin N Am"},{"key":"2026092314205302900_djag223-B22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41523-023-00595-2","article-title":"Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer","volume":"9","author":"Puthanmadhom Narayanan","year":"2023","journal-title":"Npj Breast Cancer"},{"key":"2026092314205302900_djag223-B23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.trecan.2021.12.007","article-title":"Role of financial toxicity in perpetuating health disparities","volume":"8","author":"Shah","year":"2022","journal-title":"Trends Cancer"},{"key":"2026092314205302900_djag223-B24","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1161\/CIR.0000000000000936","article-title":"Call to action: structural racism as a fundamental driver of health disparities: a presidential advisory from the American Heart Association","volume":"142","author":"Churchwell","year":"2020","journal-title":"Circulation"},{"key":"2026092314205302900_djag223-B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026092314205302900_djag223-B26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3322\/caac.21271","article-title":"A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change","volume":"65","author":"Daly","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2026092314205302900_djag223-B27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-030-20301-6_3","article-title":"Health and racial disparity in breast cancer","volume":"1152","author":"Yedjou","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"2026092314205302900_djag223-B28","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1200\/jco.2014.57.1349","article-title":"Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors","volume":"33","author":"Warner","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026092314205302900_djag223-B29","doi-asserted-by":"publisher","first-page":"e13739","DOI":"10.1200\/JCO.2024.42.16_suppl.e13739","article-title":"Disparities in patients with HER2-positive breast cancer receiving optimal treatment: analysis of the real-world ASCO CancerLinQ dataset","volume":"42","author":"Kantor","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026092314205302900_djag223-B30","doi-asserted-by":"publisher","first-page":"22715","DOI":"10.1038\/s41598-024-73617-z","article-title":"Trends in 5-year cancer survival disparities by race and ethnicity in the US between 2002\u20132006 and 2015\u20132019","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"2026092314205302900_djag223-B31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cncr.23131","article-title":"Racial and ethnic differences in breast cancer survival","volume":"112","author":"Curtis","year":"2008","journal-title":"Cancer"},{"key":"2026092314205302900_djag223-B32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10549-022-06830-x","article-title":"Exploring the intersectionality of race\/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000\u20132016","volume":"197","author":"Moore","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"2026092314205302900_djag223-B33","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1038\/s41467-021-27093-y","article-title":"HER2\u2009+\u2009breast cancers evade anti-HER2 therapy via a switch in driver pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Nat Commun"},{"key":"2026092314205302900_djag223-B34","doi-asserted-by":"publisher","first-page":"e233329","DOI":"10.1001\/jamanetworkopen.2023.3329","article-title":"Racial disparities in pathological complete response among patients receiving neoadjuvant chemotherapy for early-stage breast cancer","volume":"6","author":"Zhao","year":"2023","journal-title":"JAMA Network Open"},{"key":"2026092314205302900_djag223-B35","doi-asserted-by":"publisher","first-page":"e2348814","DOI":"10.1001\/jamanetworkopen.2023.48814","article-title":"Association of PIK3CA mutation with pathologic complete response and outcome by hormone receptor status and intrinsic subtype in early-stage ERBB2\/HER2-positive breast cancer","volume":"6","author":"Zagami","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026092314205302900_djag223-B36","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.Sabcs25-ps5-01-15","article-title":"Abstract PS5-01-15: Real-world effectiveness of trastuzumab deruxtecan in HER2+ metastatic breast cancer by racial and ethnic group - Data from US community practices","volume":"32","author":"Mehta","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026092314205302900_djag223-B37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.amjcard.2021.02.013","article-title":"Racial and socioeconomic disparities in cardiotoxicity among women with HER2-positive breast cancer","volume":"147","author":"Al-Sadawi","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026092314205302900_djag223-B38","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.31260","article-title":"Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer","volume":"124","author":"Litvak","year":"2018","journal-title":"Cancer"},{"key":"2026092314205302900_djag223-B39","doi-asserted-by":"publisher","first-page":"101613","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"2026092314205302900_djag223-B40","doi-asserted-by":"publisher","first-page":"e2344517","DOI":"10.1001\/jamanetworkopen.2023.44517","article-title":"Racial and ethnic disparity in preoperative chemosensitivity and survival in patients with early-stage breast cancer","volume":"6","author":"Roy","year":"2023","journal-title":"JAMA Network Open"},{"key":"2026092314205302900_djag223-B41","doi-asserted-by":"publisher","first-page":"e4531","DOI":"10.1371\/journal.pone.0004531","article-title":"Differences in the tumor microenvironment between African-American and European-American breast cancer patients","volume":"4","author":"Martin","year":"2009","journal-title":"PLoS One"},{"key":"2026092314205302900_djag223-B42","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jnci\/djaa215","article-title":"Breast tumor microenvironment in Black women: a distinct signature of CD8+ T-cell exhaustion","volume":"113","author":"Yao","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026092314205302900_djag223-B43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13058-020-01297-4","article-title":"Racial differences in CD8(+) T cell infiltration in breast tumors from Black and White women","volume":"22","author":"Abdou","year":"2020","journal-title":"Breast Cancer Res"},{"key":"2026092314205302900_djag223-B44","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3389\/fonc.2020.01022","article-title":"The contribution of race to breast tumor microenvironment composition and disease progression","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"key":"2026092314205302900_djag223-B45","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026092314205302900_djag223-B46","author":"Jaber","year":"2024"},{"key":"2026092314205302900_djag223-B47","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical TrialsRace-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"2026092314205302900_djag223-B48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","article-title":"Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States","volume":"208","author":"Kalinsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2026092314205302900_djag223-B49","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/op.24.00242","article-title":"Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"21","author":"Alaklabi","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026092314205302900_djag223-B50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Intern Med"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag223\/68707369\/djag223.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag223\/68707369\/djag223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:20:57Z","timestamp":1790187657000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djag223\/8726052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag223","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"djag223"}}